↓ Skip to main content

Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study

Overview of attention for article published in BMC Infectious Diseases, March 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
17 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study
Published in
BMC Infectious Diseases, March 2015
DOI 10.1186/s12879-015-0888-x
Pubmed ID
Authors

Ching-Chih Hu, Chih-Lang Lin, Liang-Che Chang, Cheng-Hung Chien, Li-Wei Chen, Ching-Jung Liu, Rong-Nan Chien

Abstract

The role of single nucleotide polymorphisms (SNPs) of interleukin (IL)-28B in predicting therapeutic response of pegylated interferon (peg-IFN) plus ribavirin (PR) for genotype 1 infected chronic hepatitis C patients with advanced fibrosis (AF) is limited. The aim of this study is to assess its role in predicting sustained virologic responses (SVR) to treatment. Forty-two patients with biopsy proven hepatitis C virus (HCV) related AF (group A; Ishak fibrosis score, ≥4) and 126 sex- and HCV genotype-matched patients without AF (group B; Ishak fibrosis score, ≤3) were recruited into study. All patients received PR therapy for 24 weeks. Baseline and on-treatment clinical, virological and host factors were evaluated for treatment efficacy. The SVR rate was significantly lower in group A than group B patients with genotype 1 infection (24% vs. 53.3%; p = 0.011). However, it was similar in those with genotype non-1 infection (76.5% vs. 76.5%; p = 1.0). IL-28B rs8099917 genotype TT is the strongest predictor for SVR in genotype 1 infection. Patients who had TT genotype and achieved RVR in group A had similar SVR rates with those in group B (44.4% vs. 53.3%; p = 0.614). One third of patients in group A developed hematological adverse effects and had required modified doses during antiviral therapy. In HCV genotype 1 infected AF receiving 24 weeks of PR treatment, patients with IL28B rs8099917 genotype TT, achieving RVR had similar SVR rate with those without AF. In contrast, patients with IL-28B rs8099917 non-TT genotype without achieving RVR are suggested to stop therapy.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 6%
Canada 1 6%
Unknown 15 88%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 24%
Other 3 18%
Student > Ph. D. Student 3 18%
Student > Bachelor 1 6%
Student > Doctoral Student 1 6%
Other 2 12%
Unknown 3 18%
Readers by discipline Count As %
Medicine and Dentistry 7 41%
Biochemistry, Genetics and Molecular Biology 2 12%
Business, Management and Accounting 1 6%
Immunology and Microbiology 1 6%
Agricultural and Biological Sciences 1 6%
Other 0 0%
Unknown 5 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2015.
All research outputs
#3,485,345
of 4,925,544 outputs
Outputs from BMC Infectious Diseases
#1,917
of 2,638 outputs
Outputs of similar age
#106,831
of 145,900 outputs
Outputs of similar age from BMC Infectious Diseases
#89
of 135 outputs
Altmetric has tracked 4,925,544 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,638 research outputs from this source. They receive a mean Attention Score of 3.1. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 145,900 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 135 others from the same source and published within six weeks on either side of this one. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.